COMPLEX ASSESSMENT OF EFFICACY OF STATINS PRESCRIBED AT MOST BY CLINICIANS
https://doi.org/10.15829/1728-8800-2018-3-22-26
Abstract
Aim. To evaluate a complex clinical efficacy, tolerability and safety of statin drugs — simvastatin, atorvastatin, rosuvastatin in patients with hyperlipidemia (HL).
Material and methods. The assessment of clinical efficacy was done in 90 patients with HL and arterial hypertension of the grades 1 and 2, age 40-75 y.o.; some of them had coronary heart disease.
Results. In 90 patients with cardiac pathology and HL, selected to 3 groups by 30 persons, the clinical efficacy of the listed statins was assessed. A significant hypolipidemic effect was noted as a decline of atherogenicity of the blood, with slight more prominent effect of rosuvastatin.
Conclusion. The data makes it to conclude the simvastatin, atorvastatin and rosuvastatin are equally effective hypolipidemic drugs in HL type IIA and IIB patients. The time frame, type and grade of positive changes in lipid profile are almost the same, and in rosuvastatin just slightly more prominent.
About the Authors
A. S. Sivkov
I. M. Sechenov First Moscow State Medical University of the Ministry of Health
Russian Federation
Moscow
Russian Federation
Moscow
E. V. Shih
I. M. Sechenov First Moscow State Medical University of the Ministry of Health
Russian Federation
Moscow
Russian Federation
Moscow
M. A. Osadchuk
I. M. Sechenov First Moscow State Medical University of the Ministry of Health
Russian Federation
Moscow
Russian Federation
Moscow
S. K. Sivkova
I. M. Sechenov First Moscow State Medical University of the Ministry of Health
Russian Federation
Moscow
Russian Federation
Moscow
N. V. Kireeva
I. M. Sechenov First Moscow State Medical University of the Ministry of Health
Russian Federation
Moscow
Russian Federation
Moscow
N. P. Chernus
I. M. Sechenov First Moscow State Medical University of the Ministry of Health
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Pityk OI, Prasol VA, Boyko VV. The choice of revascularization method in patients with critical ischemia of lower limbs. Novosti Khirurgii 2016; 24 (5): 451-6. (In Russ.)
2. Recommendations for the treatment of stable ischemic heart disease. ESC 2013. Russian Journal of Cardiology. 2014; 7: 7-79. (In Russ.)
3. Kukes VG. Metabolism of medicinal products: scientific basis of personalized medicine. M.: GEOTARMED, 2008. (In Russ.)
4. Kukes VG. Clinical Pharmacology. M.: GEOTARMED, 2016. 1024 р. (In Russ.)
5. Bouitbir J, Charles AL, Echaniz-Laguna A, et al. Opposite effects of statins on mitochondria of cardiac and skeletal muscles: A ‘mitohormesis’ mechanism involving reactive oxygen species and PGC-1. Eur Heart J 2012; 33: 1397-407. DOI: 10.1093/eurheartj/ehr224.
6. Boulanger-Piette A, Bergeron J, Desgreniers J, et al. Statin intolerance and associated muscular dysfunctions. Med Sci (Paris) 2015; 31 (12): 1109-14. DOI: 10.1051/medsci/20153112014.
7. Bucciarelli P, de Stefano V, Passomonti SM. Influence of proband’s characteristics on the risk for venous thromboembolism in relatives with factor V Leiden or prothrombin G 2020 A polymorphism. Blood 2013; 10, 22 (15): 2555-61. 373. DOI: 10.1182/blood-2013-05503649.
8. Carden D, Grander D. Pathophysiology of ischemia-reperfusion injury. Аnatomy, physiology and pathology. Nova Science Publishers Inc 2012; 25-52. ISBN: 9781619427396.
9. Cece-Esencan EN, Fontaine F, Plasencia G, et al. Software-aided cytochrome P450 reaction phenotyping and kinetic analysis in early drug discovery. Rapid Commun Mass Spectrom 2016; 30 (2): 301-10. DOI: 10.1002/rcm.7429.
10. Costa ED, Rezende BA, Cortes SF, Lemos VS. Neuronal Nitric Oxide Synthase in Vascular Physiology and Diseases. Front Physiol 2016; 7: 206. DOI: 10.3389/fphys.2016.00206.
11. Elmadbouh I, Elghobashy Y, Abd-Allah E, et al. Relationship of apolipoprotein E polymorphism with lipid profiles in atherosclerotic coronary artery disease. Egyptian Heart Journal. 2013;65 (2):71-8 DOI: 10.1016/j.ehj.2012.11.002
12. Perez Botero J, Ormsby WD, Ashrani AA, et al. Do incident and recurrent venous thromboembolism risks truly differ between heterozygous and homozygous Factor V Leiden carriers? A retrospective cohort study. Eur J Intern Med 2016; 30: 77-81. DOI: 10.1016/j.ejim.2016.02.023.
13. Savoy C, Van Lieshout RJ, Steiner M. Is Plasminogen Activator Inihibitor-1 a Physiological Bottleneck Bridging Major Depressive Disorder (MDD) and Cardiovascular Disease (CVD)? Acta Physiol (Oxf) 2016; 715-27. DOI: 10.1111/apha.12726.
Review
For citations:
Sivkov A.S., Shih E.V., Osadchuk M.A., Sivkova S.K., Kireeva N.V., Chernus N.P. COMPLEX ASSESSMENT OF EFFICACY OF STATINS PRESCRIBED AT MOST BY CLINICIANS. Cardiovascular Therapy and Prevention. 2018;17(3):22-26. (In Russ.) https://doi.org/10.15829/1728-8800-2018-3-22-26
Views:
1622
Email this article 
